Tirzepatid is a new type of dual receptor like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide), which is administered once a week. Both GLP-1 and GIP are incretins, which are chemical peptides secreted by the gastrointestinal mucosa of the human body. The former can bind to the receptors on pancreatic islet cells and stimulate insulin secretion, thereby producing a hypoglycemic effect, and can also delay gastric emptying and suppress appetite, thereby controlling weight; while the latter has the functions of inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric motility and emptying, etc., which can complement the effect of GLP-1 receptor agonists.